Menu
GeneBe

ABCC8

ATP binding cassette subfamily C member 8, the group of ATP binding cassette subfamily C

Basic information

Region (hg38): 11:17392497-17476894

Previous symbols: [ "SUR", "HRINS" ]

Links

ENSG00000006071NCBI:6833OMIM:600509HGNC:59Uniprot:Q09428AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • hyperinsulinemic hypoglycemia, familial, 1 (Definitive), mode of inheritance: AD
  • familial hyperinsulinism (Definitive), mode of inheritance: AR
  • hyperinsulinemic hypoglycemia, familial, 1 (Strong), mode of inheritance: AD
  • diabetes mellitus, permanent neonatal 3 (Strong), mode of inheritance: AD
  • hyperinsulinemic hypoglycemia, familial, 1 (Strong), mode of inheritance: AR
  • diabetes mellitus, permanent neonatal 3 (Strong), mode of inheritance: AR
  • transient neonatal diabetes mellitus (Strong), mode of inheritance: AD
  • diabetes mellitus, noninsulin-dependent (Strong), mode of inheritance: AD
  • diabetes mellitus, transient neonatal, 2 (Strong), mode of inheritance: Unknown
  • hypoglycemia, leucine-induced (Strong), mode of inheritance: AD
  • permanent neonatal diabetes mellitus (Strong), mode of inheritance: AR
  • diabetes mellitus, permanent neonatal 3 (Definitive), mode of inheritance: Semidominant
  • hyperinsulinemic hypoglycemia, familial, 1 (Definitive), mode of inheritance: Semidominant
  • maturity-onset diabetes of the young (Supportive), mode of inheritance: AD
  • DEND syndrome (Supportive), mode of inheritance: AD
  • autosomal recessive hyperinsulinism due to SUR1 deficiency (Supportive), mode of inheritance: AR
  • permanent neonatal diabetes mellitus (Supportive), mode of inheritance: AD
  • transient neonatal diabetes mellitus (Supportive), mode of inheritance: AD
  • autosomal dominant hyperinsulinism due to SUR1 deficiency (Supportive), mode of inheritance: AD
  • diazoxide-resistant focal hyperinsulinism due to SUR1 deficiency (Supportive), mode of inheritance: AD
  • diabetes mellitus, transient neonatal, 2 (Strong), mode of inheritance: AD
  • diabetes mellitus, permanent neonatal 3 (Strong), mode of inheritance: AR
  • type 2 diabetes mellitus (Limited), mode of inheritance: AD
  • hyperinsulinemic hypoglycemia, familial, 1 (Strong), mode of inheritance: AD
  • hyperinsulinemic hypoglycemia, familial, 1 (Strong), mode of inheritance: AR
  • pulmonary arterial hypertension (Moderate), mode of inheritance: AD
  • monogenic diabetes (Definitive), mode of inheritance: Semidominant

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Diabetes mellitus, transient neonatal, 2; Diabetes, permanent neonatal 3; Hyperinsulinemic hypoglycemia, familial, 1; Hypoglycemia, leucine-inducedAD/AREndocrinePrompt treatment (eg, of ketoacidosis and dehydration) can avoid morbidity; Individuals with neonatal diabetes mellitus may respond well to sulfonylurea treatment; Non-neonatally affected individuals may respond to diazoxide; Individuals with leucine-induced hypoglycemia may have episodes triggered by high-protein (high leucine) feedings, and may respond to diazoxideEndocrine7847376; 7716548; 923011; 8751851; 9727845; 10426386; 10322395; 11808881; 10334322; 1018078; 12559865; 12941782; 15356046; 15579781; 16885549; 16882742; 16613899; 8596924; 19254908; 20301620; 21716120; 23273570
Hyperinsulinemic hypoglycemia, familial, 1 inheritance may involve imprinting

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the ABCC8 gene.

  • not provided (1540 variants)
  • Hyperinsulinemic hypoglycemia, familial, 1 (470 variants)
  • Maturity onset diabetes mellitus in young (464 variants)
  • Transitory neonatal diabetes mellitus (458 variants)
  • Hereditary hyperinsulinism (188 variants)
  • not specified (179 variants)
  • Type 2 diabetes mellitus (169 variants)
  • Permanent neonatal diabetes mellitus (137 variants)
  • Diabetes mellitus, transient neonatal, 2 (134 variants)
  • Inborn genetic diseases (100 variants)
  • Familial hyperinsulinism (49 variants)
  • Diabetes mellitus, permanent neonatal 3 (29 variants)
  • ABCC8-related condition (26 variants)
  • Neonatal diabetes mellitus (24 variants)
  • Leucine-induced hypoglycemia (22 variants)
  • Diabetes mellitus, transient neonatal, 2;Hyperinsulinemic hypoglycemia, familial, 1;Leucine-induced hypoglycemia;Diabetes mellitus, permanent neonatal 3;Type 2 diabetes mellitus (17 variants)
  • Monogenic diabetes (17 variants)
  • Diabetes mellitus, transient neonatal, 2;Type 2 diabetes mellitus;Diabetes mellitus, permanent neonatal 3;Hyperinsulinemic hypoglycemia, familial, 1;Leucine-induced hypoglycemia (16 variants)
  • Diabetes mellitus, permanent neonatal 3;Diabetes mellitus, transient neonatal, 2;Hyperinsulinemic hypoglycemia, familial, 1;Leucine-induced hypoglycemia;Type 2 diabetes mellitus (11 variants)
  • Hyperinsulinism, Dominant/Recessive (9 variants)
  • Transient Neonatal Diabetes, Dominant (9 variants)
  • Leucine-induced hypoglycemia;Diabetes mellitus, transient neonatal, 2;Hyperinsulinemic hypoglycemia, familial, 1;Type 2 diabetes mellitus;Diabetes mellitus, permanent neonatal 3 (8 variants)
  • Diabetes mellitus, transient neonatal, 2;Hyperinsulinemic hypoglycemia, familial, 1;Leucine-induced hypoglycemia;Type 2 diabetes mellitus;Diabetes mellitus, permanent neonatal 3 (8 variants)
  • Hyperinsulinemic hypoglycemia, familial, 1;Leucine-induced hypoglycemia;Diabetes mellitus, permanent neonatal 3;Diabetes mellitus, transient neonatal, 2;Type 2 diabetes mellitus (5 variants)
  • Type 2 diabetes mellitus;Hyperinsulinemic hypoglycemia, familial, 1;Leucine-induced hypoglycemia;Diabetes mellitus, permanent neonatal 3;Diabetes mellitus, transient neonatal, 2 (4 variants)
  • Diabetes mellitus, permanent neonatal 3;Hyperinsulinemic hypoglycemia, familial, 1;Leucine-induced hypoglycemia;Diabetes mellitus, transient neonatal, 2;Type 2 diabetes mellitus (4 variants)
  • Type 2 diabetes mellitus;Hyperinsulinemic hypoglycemia, familial, 1;Diabetes mellitus, transient neonatal, 2;Leucine-induced hypoglycemia;Diabetes mellitus, permanent neonatal 3 (4 variants)
  • Leucine-induced hypoglycemia;Type 2 diabetes mellitus;Diabetes mellitus, permanent neonatal 3;Diabetes mellitus, transient neonatal, 2;Hyperinsulinemic hypoglycemia, familial, 1 (4 variants)
  • Type 2 diabetes mellitus;Leucine-induced hypoglycemia;Diabetes mellitus, transient neonatal, 2;Hyperinsulinemic hypoglycemia, familial, 1;Diabetes mellitus, permanent neonatal 3 (3 variants)
  • ABCC8-related disorders (3 variants)
  • Type 2 diabetes mellitus;Leucine-induced hypoglycemia;Hyperinsulinemic hypoglycemia, familial, 1;Diabetes mellitus, transient neonatal, 2;Diabetes mellitus, permanent neonatal 3 (3 variants)
  • Hyperinsulinemic hypoglycemia, familial, 1;Diabetes mellitus, permanent neonatal 3 (3 variants)
  • Diabetes mellitus, permanent neonatal 3;Type 2 diabetes mellitus;Diabetes mellitus, transient neonatal, 2;Hyperinsulinemic hypoglycemia, familial, 1;Leucine-induced hypoglycemia (3 variants)
  • Diabetes mellitus, transient neonatal, 2;Type 2 diabetes mellitus;Hyperinsulinemic hypoglycemia, familial, 1;Leucine-induced hypoglycemia;Diabetes mellitus, permanent neonatal 3 (3 variants)
  • Diabetes mellitus, permanent neonatal 3;Hyperinsulinemic hypoglycemia, familial, 1;Leucine-induced hypoglycemia;Type 2 diabetes mellitus;Diabetes mellitus, transient neonatal, 2 (3 variants)
  • Type 2 diabetes mellitus;Diabetes mellitus, permanent neonatal 3;Hyperinsulinemic hypoglycemia, familial, 1;Leucine-induced hypoglycemia;Diabetes mellitus, transient neonatal, 2 (3 variants)
  • 12 conditions (3 variants)
  • Type 2 diabetes mellitus;Diabetes mellitus, transient neonatal, 2;Diabetes mellitus, permanent neonatal 3;Hyperinsulinemic hypoglycemia, familial, 1;Leucine-induced hypoglycemia (3 variants)
  • Hyperinsulinemic hypoglycemia, familial, 1;Leucine-induced hypoglycemia;Type 2 diabetes mellitus;Diabetes mellitus, permanent neonatal 3;Diabetes mellitus, transient neonatal, 2 (2 variants)
  • Type 2 diabetes mellitus;Permanent neonatal diabetes mellitus;Diabetes mellitus, transient neonatal, 2;Hyperinsulinemic hypoglycemia, familial, 1;Leucine-induced hypoglycemia (2 variants)
  • Neonatal hypoglycemia (2 variants)
  • Hyperinsulinemia (2 variants)
  • Hypoglycemia (2 variants)
  • Hyperinsulinemic hypoglycemia, familial, 1;Leucine-induced hypoglycemia;Diabetes mellitus, transient neonatal, 2;Diabetes mellitus, permanent neonatal 3;Type 2 diabetes mellitus (2 variants)
  • Hyperinsulinemic hypoglycemia, familial, 1;Leucine-induced hypoglycemia;Permanent neonatal diabetes mellitus;Diabetes mellitus, transient neonatal, 2;Type 2 diabetes mellitus (2 variants)
  • Type 2 diabetes mellitus;Leucine-induced hypoglycemia;Hyperinsulinemic hypoglycemia, familial, 1;Permanent neonatal diabetes mellitus;Diabetes mellitus, transient neonatal, 2 (1 variants)
  • ABCC8-related disorder (1 variants)
  • Congenital isolated hyperinsulinism (1 variants)
  • Hereditary disease (1 variants)
  • See cases (1 variants)
  • Hyperinsulinemic hypoglycemia, familial, 1;Leucine-induced hypoglycemia;Type 2 diabetes mellitus;Permanent neonatal diabetes mellitus;Diabetes mellitus, transient neonatal, 2 (1 variants)
  • Autosomal dominant hyperinsulinism due to SUR1 deficiency (1 variants)
  • Leucine-induced hypoglycemia;Hyperinsulinemic hypoglycemia, familial, 1;Diabetes mellitus, transient neonatal, 2;Diabetes mellitus, permanent neonatal 3;Type 2 diabetes mellitus (1 variants)
  • Obesity (1 variants)
  • Diabetes mellitus, transient neonatal, 2;Diabetes mellitus, permanent neonatal 3;Hyperinsulinemic hypoglycemia, familial, 1;Leucine-induced hypoglycemia;Type 2 diabetes mellitus (1 variants)
  • Cerebral edema (1 variants)
  • Diabetes mellitus, permanent neonatal 3;Hyperinsulinemic hypoglycemia, familial, 1 (1 variants)
  • Hyperinsulinemic hypoglycemia, familial, 1;Leucine-induced hypoglycemia;Diabetes mellitus, permanent neonatal 3 (1 variants)
  • Diabetes mellitus, transient neonatal, 2;Leucine-induced hypoglycemia;Hyperinsulinemic hypoglycemia, familial, 1;Diabetes mellitus, permanent neonatal 3;Type 2 diabetes mellitus (1 variants)
  • Type 2 diabetes mellitus;Diabetes mellitus, transient neonatal, 2;Hyperinsulinemic hypoglycemia, familial, 1;Leucine-induced hypoglycemia;Diabetes mellitus, permanent neonatal 3 (1 variants)
  • Leucine-induced hypoglycemia;Type 2 diabetes mellitus;Diabetes mellitus, transient neonatal, 2;Hyperinsulinemic hypoglycemia, familial, 1;Diabetes mellitus, permanent neonatal 3 (1 variants)
  • Hyperinsulinemic hypoglycemia, familial, 1;Diabetes mellitus, permanent neonatal 3;Diabetes mellitus, transient neonatal, 2;Type 2 diabetes mellitus;Leucine-induced hypoglycemia (1 variants)
  • Hyperinsulinemic hypoglycemia, familial, 1;Leucine-induced hypoglycemia;Type 2 diabetes mellitus;Diabetes mellitus, transient neonatal, 2;Diabetes mellitus, permanent neonatal 3 (1 variants)
  • Pulmonary arterial hypertension (1 variants)
  • Diabetes mellitus, transient neonatal, 2;Leucine-induced hypoglycemia;Hyperinsulinemic hypoglycemia, familial, 1;Type 2 diabetes mellitus;Diabetes mellitus, permanent neonatal 3 (1 variants)
  • Diabetes mellitus (1 variants)
  • Permanent neonatal diabetes mellitus;Diabetes mellitus, transient neonatal, 2;Hyperinsulinemic hypoglycemia, familial, 1;Leucine-induced hypoglycemia;Type 2 diabetes mellitus (1 variants)
  • Hyperinsulinemic hypoglycemia, familial, 1;Leucine-induced hypoglycemia;Diabetes mellitus, permanent neonatal 3;Type 2 diabetes mellitus;Diabetes mellitus, transient neonatal, 2 (1 variants)
  • Diabetes mellitus, transient neonatal, 2;Diabetes mellitus, permanent neonatal 3;Type 2 diabetes mellitus;Hyperinsulinemic hypoglycemia, familial, 1;Leucine-induced hypoglycemia (1 variants)
  • Type 2 diabetes mellitus;Diabetes mellitus, permanent neonatal 3;Diabetes mellitus, transient neonatal, 2;Hyperinsulinemic hypoglycemia, familial, 1;Leucine-induced hypoglycemia (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the ABCC8 gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
18
clinvar
548
clinvar
4
clinvar
570
missense
22
clinvar
77
clinvar
299
clinvar
11
clinvar
1
clinvar
410
nonsense
37
clinvar
31
clinvar
68
start loss
3
clinvar
1
clinvar
4
frameshift
41
clinvar
51
clinvar
3
clinvar
95
inframe indel
1
clinvar
14
clinvar
15
splice donor/acceptor (+/-2bp)
17
clinvar
42
clinvar
3
clinvar
62
splice region
17
97
1
115
non coding
4
clinvar
21
clinvar
159
clinvar
71
clinvar
255
Total 120 207 358 718 76

Highest pathogenic variant AF is 0.0000329

Variants in ABCC8

This is a list of pathogenic ClinVar variants found in the ABCC8 region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
11-17392873-T-C Hyperinsulinism, Dominant/Recessive • Permanent neonatal diabetes mellitus • Transient Neonatal Diabetes, Dominant • Transitory neonatal diabetes mellitus • Maturity onset diabetes mellitus in young Conflicting classifications of pathogenicity (Jun 14, 2016)368948
11-17392898-A-T Diabetes mellitus, transient neonatal, 2 • Hyperinsulinemic hypoglycemia, familial, 1 • Permanent neonatal diabetes mellitus • Maturity onset diabetes mellitus in young • Transitory neonatal diabetes mellitus Uncertain significance (Jan 13, 2018)303746
11-17392984-T-G not specified Uncertain significance (Nov 10, 2020)1338613
11-17393004-C-G Uncertain significance (Dec 23, 2022)2812639
11-17393004-C-T Hereditary hyperinsulinism • not specified • Transitory neonatal diabetes mellitus • Maturity onset diabetes mellitus in young Conflicting classifications of pathogenicity (Apr 12, 2021)804493
11-17393008-C-T Uncertain significance (Aug 22, 2022)2171714
11-17393009-G-A not specified • Maturity onset diabetes mellitus in young • Transient Neonatal Diabetes, Dominant • Hyperinsulinism, Dominant/Recessive • Permanent neonatal diabetes mellitus • Diabetes mellitus, transient neonatal, 2 • Hyperinsulinemic hypoglycemia, familial, 1 • Hereditary hyperinsulinism • Inborn genetic diseases Conflicting classifications of pathogenicity (Jan 31, 2024)157706
11-17393015-G-A Likely benign (Sep 05, 2023)1080359
11-17393015-G-C Likely benign (Oct 31, 2022)1997506
11-17393017-C-T Uncertain significance (Sep 01, 2021)1443657
11-17393018-G-A Likely benign (Nov 17, 2023)1157880
11-17393023-C-T not specified • Transient Neonatal Diabetes, Dominant • Maturity onset diabetes mellitus in young • Hyperinsulinism, Dominant/Recessive • Permanent neonatal diabetes mellitus • Diabetes mellitus, transient neonatal, 2 • Hyperinsulinemic hypoglycemia, familial, 1 • Leucine-induced hypoglycemia • Diabetes mellitus, permanent neonatal 3 • Hereditary hyperinsulinism • Neonatal hypoglycemia Conflicting classifications of pathogenicity (Feb 01, 2024)157705
11-17393024-G-A Hereditary hyperinsulinism • Transitory neonatal diabetes mellitus • Maturity onset diabetes mellitus in young Conflicting classifications of pathogenicity (Jun 06, 2023)989950
11-17393027-G-A Likely benign (May 22, 2023)2841388
11-17393030-C-T Likely benign (Nov 24, 2023)1098089
11-17393033-C-G Likely benign (Sep 12, 2023)2713814
11-17393033-C-T Likely benign (Aug 02, 2023)2967054
11-17393034-C-T Hereditary hyperinsulinism • Transitory neonatal diabetes mellitus • Maturity onset diabetes mellitus in young Conflicting classifications of pathogenicity (Jan 25, 2024)767064
11-17393035-G-T Likely benign (Oct 18, 2023)2893329
11-17393039-G-A Likely benign (May 07, 2023)2775626
11-17393047-T-C Hyperinsulinemic hypoglycemia, familial, 1 • Diabetes mellitus, transient neonatal, 2 • Permanent neonatal diabetes mellitus Conflicting classifications of pathogenicity (Jan 27, 2024)303747
11-17393051-T-C Likely benign (May 04, 2022)1955304
11-17393051-TG-T Hyperinsulinemic hypoglycemia, familial, 1 • Transitory neonatal diabetes mellitus • Maturity onset diabetes mellitus in young Conflicting classifications of pathogenicity (Mar 24, 2017)550926
11-17393054-C-T Likely benign (Mar 09, 2023)2840106
11-17393060-G-A Diabetes mellitus, transient neonatal, 2;Hyperinsulinemic hypoglycemia, familial, 1;Leucine-induced hypoglycemia;Diabetes mellitus, permanent neonatal 3;Type 2 diabetes mellitus • not specified Likely benign (Dec 09, 2023)1094174

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
ABCC8protein_codingprotein_codingENST00000389817 3984018
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
7.96e-240.99912563201161257480.000461
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense1.917529150.8220.000059310229
Missense in Polyphen159231.980.685412681
Synonymous-0.8534093881.060.00002683228
Loss of Function3.355184.20.6060.00000456892

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.0007850.000771
Ashkenazi Jewish0.00009930.0000992
East Asian0.0003860.000326
Finnish0.0002380.000231
European (Non-Finnish)0.0005570.000554
Middle Eastern0.0003860.000326
South Asian0.0005910.000588
Other0.0001630.000163

dbNSFP

Source: dbNSFP

Function
FUNCTION: Subunit of the beta-cell ATP-sensitive potassium channel (KATP). Regulator of ATP-sensitive K(+) channels and insulin release. {ECO:0000269|PubMed:24814349, ECO:0000269|PubMed:25720052}.;
Disease
DISEASE: Leucine-induced hypoglycemia (LIH) [MIM:240800]: Rare cause of hypoglycemia and is described as a condition in which symptomatic hypoglycemia is provoked by high protein feedings. Hypoglycemia is also elicited by administration of oral or intravenous infusions of a single amino acid, leucine. {ECO:0000269|PubMed:15356046}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Familial hyperinsulinemic hypoglycemia 1 (HHF1) [MIM:256450]: Most common cause of persistent hypoglycemia in infancy. Unless early and aggressive intervention is undertaken, brain damage from recurrent episodes of hypoglycemia may occur. {ECO:0000269|PubMed:10202168, ECO:0000269|PubMed:10334322, ECO:0000269|PubMed:10615958, ECO:0000269|PubMed:11018078, ECO:0000269|PubMed:11226335, ECO:0000269|PubMed:11867634, ECO:0000269|PubMed:12364426, ECO:0000269|PubMed:12941782, ECO:0000269|PubMed:15562009, ECO:0000269|PubMed:15579781, ECO:0000269|PubMed:15807877, ECO:0000269|PubMed:16357843, ECO:0000269|PubMed:16429405, ECO:0000269|PubMed:24814349, ECO:0000269|PubMed:25720052, ECO:0000269|PubMed:8650576, ECO:0000269|PubMed:8751851, ECO:0000269|PubMed:8923011, ECO:0000269|PubMed:9618169, ECO:0000269|PubMed:9648840, ECO:0000269|PubMed:9769320}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Diabetes mellitus, permanent neonatal (PNDM) [MIM:606176]: A rare form of diabetes distinct from childhood- onset autoimmune diabetes mellitus type 1. It is characterized by insulin-requiring hyperglycemia that is diagnosed within the first months of life. Permanent neonatal diabetes requires lifelong therapy. {ECO:0000269|PubMed:16613899, ECO:0000269|PubMed:16885549, ECO:0000269|PubMed:17213273, ECO:0000269|PubMed:17668386}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Transient neonatal diabetes mellitus 2 (TNDM2) [MIM:610374]: Neonatal diabetes is a form of diabetes mellitus defined by the onset of mild-to-severe hyperglycemia within the first months of life. Transient neonatal diabetes remits early, with a possible relapse during adolescence. {ECO:0000269|PubMed:16885549}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
Type II diabetes mellitus - Homo sapiens (human);ABC transporters - Homo sapiens (human);Insulin secretion - Homo sapiens (human);Anti-diabetic Drug Potassium Channel Inhibitors Pathway, Pharmacodynamics;Antiarrhythmic Pathway, Pharmacodynamics;Disopyramide Action Pathway;Procainamide (Antiarrhythmic) Action Pathway;Phenytoin (Antiarrhythmic) Action Pathway;Fosphenytoin (Antiarrhythmic) Action Pathway;Bopindolol Action Pathway;Timolol Action Pathway;Carteolol Action Pathway;Bevantolol Action Pathway;Practolol Action Pathway;Glibenclamide Action Pathway;Gliclazide Action Pathway;Dobutamine Action Pathway;Isoprenaline Action Pathway;Arbutamine Action Pathway;Amiodarone Action Pathway;Levobunolol Action Pathway;Metipranolol Action Pathway;Mexiletine Action Pathway;Lidocaine (Antiarrhythmic) Action Pathway;Quinidine Action Pathway;Sotalol Action Pathway;Epinephrine Action Pathway;Betaxolol Action Pathway;Atenolol Action Pathway;Alprenolol Action Pathway;Acebutolol Action Pathway;Muscle/Heart Contraction;Diltiazem Action Pathway;Propranolol Action Pathway;Pindolol Action Pathway;Penbutolol Action Pathway;Oxprenolol Action Pathway;Metoprolol Action Pathway;Esmolol Action Pathway;Bisoprolol Action Pathway;Bupranolol Action Pathway;Nebivolol Action Pathway;Amlodipine Action Pathway;Verapamil Action Pathway;Nitrendipine Action Pathway;Nisoldipine Action Pathway;Nimodipine Action Pathway;Ibutilide Action Pathway;Tocainide Action Pathway;Flecainide Action Pathway;Pancreas Function;Isradipine Action Pathway;Nifedipine Action Pathway;Felodipine Action Pathway;Nadolol Action Pathway;Carvedilol Action Pathway;Labetalol Action Pathway;Repaglinide Action Pathway;Nateglinide Action Pathway;Defective ABCC8 can cause hypoglycemias and hyperglycemias;Disorders of transmembrane transporters;Disease;Metabolism;Regulation of insulin secretion;Neuronal System;ATP sensitive Potassium channels;Integration of energy metabolism;ABC transporter disorders;Inwardly rectifying K+ channels;Potassium Channels;FOXA2 and FOXA3 transcription factor networks (Consensus)

Recessive Scores

pRec
0.435

Intolerance Scores

loftool
0.0423
rvis_EVS
-2.09
rvis_percentile_EVS
1.57

Haploinsufficiency Scores

pHI
0.150
hipred
Y
hipred_score
0.771
ghis
0.635

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.718

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Abcc8
Phenotype
endocrine/exocrine gland phenotype; homeostasis/metabolism phenotype;

Gene ontology

Biological process
cellular glucose homeostasis;potassium ion transport;female pregnancy;memory;visual learning;response to pH;response to zinc ion;negative regulation of low-density lipoprotein particle clearance;negative regulation of angiogenesis;response to lipopolysaccharide;positive regulation of tumor necrosis factor production;response to insulin;response to drug;negative regulation of insulin secretion;regulation of insulin secretion;transmembrane transport;negative regulation of glial cell proliferation;negative regulation of wound healing;negative regulation of neuroblast migration;cellular response to organic substance;potassium ion transmembrane transport;positive regulation of uterine smooth muscle relaxation;positive regulation of voltage-gated potassium channel activity;positive regulation of tight junction disassembly;negative regulation of maintenance of permeability of blood-brain barrier
Cellular component
mitochondrion;plasma membrane;inward rectifying potassium channel;membrane;synaptic vesicle membrane;sarcolemma
Molecular function
potassium channel activity;ATP binding;sulfonylurea receptor activity;ATP-activated inward rectifier potassium channel activity;ATPase activity, coupled to transmembrane movement of substances;ion channel binding